Featured Product
This Week in Quality Digest Live
FDA Compliance Features
Jón Bergsteinsson
Understanding the standard is essential
Stephanie Ojeda
The FDA’s new QMSR will harmonize with ISO 13485 for medical device quality management
Steve Thompson
An excellent technological tool that improves quality and compliance
Kelley Jacobsen
Amid rising prices, medical device supply chains need greater scrutiny and standardization
Jennifer Chu
Findings point to faster way to find bacteria in food, water, and clinical samples

More Features

FDA Compliance News
Streamlines annual regulatory review for life sciences
Facilitates quick sanitary compliance and production changeover
Creates one of the most comprehensive regulatory SaaS platforms for the industry
Company’s first funding round will be used to accelerate product development for its QMS and MES SaaS offerings
Showcasing tech, solutions, and services at Gulfood Manufacturing 2022
Easy, reliable leak testing with methylene blue
Now is not the time to skip critical factory audits and supply chain assessments
Google Docs collaboration, more efficient management of quality deviations
Delivers time, cost, and efficiency savings while streamlining compliance activity

More News

Michael Causey

FDA Compliance

Medical Device CEO Laments ‘Anti-Industry’ FDA Culture

Is the agency stifling medical innovation?

Published: Wednesday, April 18, 2012 - 10:16

While calling it one of the more “egregious” examples he’s seen or heard about, Fisher Wallace Labs (FWL) CEO Chip Fisher said the Food and Drug Administration’s (FDA) attempt to “force its own agenda” over dissenting science or how its own advisory boards vote on medical device classification is just part of a broader “systemic” problem with some at the agency.

As reported earlier in Medical Device Daily and elsewhere, an FDA advisory committee hearing in February for cranial electrotherapy stimulator (CES) medical devices was flawed, in part FWL alleges, because the FDA violated its own rules in running the hearing. FWL filed a March 9, 2012, citizen’s petition challenging the FDA’s proposed classification of CES devices as high-risk or Class III devices.

Kelly Roman, FWL’s vice president, said he’s “heartened,” however, that the FDA has said publicly that it will discuss the situation directly with FWL. “The fact that they responded at all” is unusual for the agency in a case like this, and Roman believes it bodes well for FWL’s desire to have its CES keep its Class I designation.

But Fisher worries that this kind of FDA activity is stifling medical innovation, especially for smaller companies that may not be able to afford a long and drawn-out battle like this with the agency.

“I think there’s a growing culture of anti-industry” at the FDA, Fisher says. Specifically, he criticized a faction at the FDA for “picking apart” and using aspects of research to prove the point it wanted to prove, but not always considering the full body of research that might support another position.

Roman doesn’t expect to hear from the FDA for many months and has gotten no official timetable from the agency. “We appreciate that the FDA is a big slow-moving ship,” he notes.

For a glimpse at some of the February hearing that troubled FWL, click here.

This article first appeared in the April 11, 2012, edition of the AssurX blog.


About The Author

Michael Causey’s picture

Michael Causey

James Michael Causey’s been a journalist since he started his own neighborhood newspaper in the 1970s. In addition to quizzing FDA officials for the past 10+ years, he’s also interviewed political satirist Art Buchwald, FCC Chairman Reed Hundt, SEC Chairwoman Mary Schapiro, and is the past president of the Washington Independent Writers. Causey is the editor and publisher of eDataIntegrityReport.com and is a contributing writer on the AssurXblog.